💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the development, manufacturing & sale of pharmaceutical products and services& trading of commodities and renting of properties. The Company…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, trading cheap versus its own history.
Syncom Formulations is scored on the pharma / healthcare framework. It keeps a healthy 14.7% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.76×) — worth a closer look. Free cash flow is worth about 0.4% of its market value.
Over the last 3 years revenue compounded at 30%/yr and profit at 56%/yr. Book value itself has compounded 18%/yr — the hallmark of a genuine compounder. Return on equity is an elite 18.4%. In the latest quarter profit fell 1% versus the prior quarter.
At 25× earnings, the stock sits at the 19th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~10%/yr earnings growth for a decade. The books come through clean — a forensic grade of B, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 22.18 | — | — |
| P/B | 4.57 | 4.11 | worse |
| EV/EBITDA | 16.19 | 19.15 | better |
| ROE | 18.42 | — | — |
| ROCE | 24.46 | 6.87 | better |
| ROA | 16.02 | — | — |
| Quick Ratio | 2.58 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 30% CAGR over 3 years — high-growth territory. Growth is decelerating — latest year grew slower than the year before.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (56% vs 30%) — margin expansion is at work. The latest year saw a +55% swing — check if it's a one-off or structural.
Operating margin has expanded from 11% to 19% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 18% — a respectable return on shareholder capital. Capital efficiency improving — ROE up 11pp across the window.
EPS has grown every year — each share earns more than the last, consistently. Profit grew faster than EPS (56% vs 50%) — share dilution is eroding per-share value. 50% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
1 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 11% QoQ — could be seasonality or a genuine slowdown. Run-rate stepping up — recent quarters average 14% above earlier ones.
Quarterly net margins are expanding (13% → 19%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 50.6% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.